Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Different Reversal Agents in Pediatric Day-case Cancer Surgery

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
Saite tiek saglabāta starpliktuvē
StatussVēl nepieņem darbā
Sponsori
National Cancer Institute, Egypt

Atslēgvārdi

Abstrakts

The aim of this study was to compare the efficacy of sugammadex and neostigmine on
reversing neuromuscular blockers in pediatric patients undergoing outpatient surgical
procedures.

Apraksts

Postoperative residual curarization (PORC)" a residual duration of action of muscle relaxants beyond the end of the operation" in postoperative patients is a succession of the presence of blocked nicotinic receptors. Even in observationally asymptomatic patients, 60-70% of these receptors can be still blocked. PORC can cause delayed recovery, hypoxia, metabolic derangement and rarely death. Cholinesterase inhibitors are traditionally used for reversal of neuromuscular blockade (NMB). Among these agents neostigmine is the most potent and selective one. Cholinesterase inhibitors have multisystemic side effects. Since these agents are not selective to nicotinic receptors and also stimulate the muscarinic system, there can be quite a few serious adverse effects as follows: Bradycardia, QT lengthening, bronchoconstriction, hypersalivation and increased motility. To avoid these effects, concomitant anticholinergic agents, such as atropine or glycopyrolate, are administered to the patient. The incidence of PORC is still high with the prevalence of a train-of-four (TOF) ratio of less than 0.9 found in the postoperative recovery unit. Recent studies have been able to link even low levels of residual paralysis (TOF ratio <0.9) with significant impairment of pharyngeal muscle function, hypoxic ventilatory drive and decreased respiratory function in the immediate postoperative period.

Despite the knowledge of such side effects, and despite the introduction of various new neuromuscular blocking agents (NMBA) such as rocuronium or mivacurium over the last 15 years, no significant reduction in the incidence of residual neuromuscular blockade has so far been observable.

Today, sugammadex is an alternative to the decurarization procedure, which was traditionally executed with cholinesterase inhibitors. Sugammadex a γ-cyclodextrin with a high affinity to rocuronium and other aminosteroidal NMBA that allows the rapid and complete reversal of especially rocuronium-induced neuromuscular blockade, has raised hopes to overcome the problem of residual neuromuscular blockade. Sugammadex is proved to be a safe and superior agent in NMB reversal compared to neostigmine in adults.

PORC and the muscarinic side effects are not anticipated when using sugammadex,.

Also, due to its pharmacodynamic profile, sugammadex, in combination with rocuronium, have the potential to displace succinylcholine as the "gold standard" muscle relaxant for rapid sequence induction.

The rudimentary neuromuscular junction, the variability of fibrin fibers, the differences in drug distribution and body volume in children change their neuromuscular conduction. These factors can cause prolonged recovery and increased risk of PORC. However, there is few studies in the literature concerning sugammadex administration in pediatric patients.

Datumi

Pēdējoreiz pārbaudīts: 05/31/2019
Pirmais iesniegtais: 06/17/2019
Paredzētā reģistrācija iesniegta: 06/20/2019
Pirmais izlikts: 06/24/2019
Pēdējais atjauninājums iesniegts: 06/20/2019
Pēdējā atjaunināšana ievietota: 06/24/2019
Faktiskais studiju sākuma datums: 05/31/2019
Paredzamais primārās pabeigšanas datums: 08/31/2019
Paredzamais pētījuma pabeigšanas datums: 09/30/2019

Stāvoklis vai slimība

Post-operative Residual Curarization

Iejaukšanās / ārstēšana

Drug: Group S

Drug: Group N

Fāze

Fāze 4

Roku grupas

RokaIejaukšanās / ārstēšana
Experimental: Group S
Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg
Drug: Group S
Reversal of neuromuscular blockers
Active Comparator: Group N
Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg
Drug: Group N
Reversal of neuromuscular blockers

Atbilstības kritēriji

Vecums, kas piemērots studijām 2 Years Uz 2 Years
Dzimumi, kas ir piemēroti studijāmAll
Pieņem veselīgus brīvprātīgos
Kritēriji

Inclusion Criteria:

- Age ≥2 years and < 18 years.

- American society of anesthesiologists (ASA) status 1-3.

- patients undergoing outpatient procedures

Exclusion Criteria:

- Known drug hypersensitivity.-

- History of renal or hepatic failure.

- Diseases of the neuromuscular junction.

- history of malignant hyperthermia.

Rezultāts

Primārie rezultāti

1. Recovery time [time from reversal administration until TOF ratio reaches0.9%, ranging from 1 to 2.5 minutes, measured withThe train-of-four (TOF) equipment working with the nerve-muscle acceleromyometry principle (TOF Draeger Medical Systems, Inc.16 Electronic Avenue,]

time from neostigmine or sugammadex administration until recovery of the TOF ratio to 0.9%

Sekundārie iznākuma mērījumi

1. extubation time [time from muscle relaxant administration until extubation,extubation will be performed based on clinical criteria extubation timeis estimated to range from 50 to 55 minutes]

time from neuromuscular blocker administration to extubation

Pievienojieties mūsu
facebook lapai

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne

  • Darbojas 55 valodās
  • Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
  • Garšaugu atpazīšana pēc attēla
  • Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
  • Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
  • Meklēt ārstniecības augus pēc to iedarbības
  • Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem

Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem

Google Play badgeApp Store badge